ArticleDiscover oncology2026
Multi-omics and spatial transcriptomics identify KCMF1 as an immune-metabolic driver of hepatocellular carcinoma progression.
Article in Discover oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hepatocellular carcinoma (HCC) is a leading cause of cancer mortality, characterized by poor prognosis and limited treatment options. Ubiquitination, a key post-translational modification, plays crucial roles in cancer progression. However, the specific contribution of ubiquitination-associated genes to HCC remains largely unexplored. Public datasets from TCGA and GEO were analyzed to identify ubiquitination-associated genes (K48 and K63 ubiquitin chains). Prognostic models were constructed using multiple regression algorithms, consistently identifying KCMF1 as the top contributor. Bulk transcriptomic analysis was performed to assess differential expression, immune infiltration, and pathway enrichment. Single-cell and spatial transcriptomic analyses further investigated KCMF1's expression and its functional role in the tumor microenvironment. KCMF1 was significantly overexpressed in HCC tissues and strongly associated with poor overall and disease-specific survival. Transcriptomic analysis revealed its positive correlation with immune cell populations enriched in the tumor microenvironment, such as M0 macrophages (naive/precursor macrophages that serve as the cellular source for TAM polarization). Functional enrichment highlighted KCMF1's involvement in VEGF and TGFβ signaling pathways, which promote angiogenesis and immune suppression. Single-cell analysis identified KCMF1-positive malignant cells as hubs of intercellular communication, while spatial transcriptomics confirmed its enrichment in malignant regions, underscoring its role in tumor-stroma interactions. KCMF1 is a pivotal ubiquitination-associated gene that drives HCC progression through immune modulation. Integrative single-cell and spatial transcriptomics further locate KCMF1-enriched malignant niches, providing spatially resolved biomarker evidence. Its consistent prognostic relevance across analyses highlights its potential as a biomarker and therapeutic target. Therefore, KCMF1-directed therapy and combined immune-metabolic interventions warrant further investigation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.